Michael Thomas Heffernan

Michael Thomas Heffernan is a declared insider at 6 companies (board member); the most frequent names are Collegium Pharmaceutical, Inc, Trevi Therapeutics, Inc. and Akebia Therapeutics, Inc. The record holds 92 filings, for trades running from 31 December 2015 to 15 September 2026.

Both buying and selling appear: 1 purchase worth €22k, against 40 sales worth €16.5M. Sales outweigh purchases by €16.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 35 share grants and 12 option exercises. Since January 2026: no purchases and 4 sales on the market.

The record was last updated on 17 September 2026 with an open-market sale (€240k) in Trevi Therapeutics, Inc. The most recent open-market purchase was published on 13 May 2019, 2,718 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.